2026-2034年全球肺炎治療市場規模、佔有率、趨勢和成長分析報告

預計肺炎治療市場將從 2025 年的 32.8 億美元成長到 2034 年的 75.2 億美元，2026 年至 2034 年的複合年成長率為 9.66%。

全球呼吸道感染疾病的高發生率正推動全球肺炎治療市場穩定成長。肺炎仍然是導致發病率和死亡率的主要原因之一，尤其是在兒童和老年人群中。人們對早期診斷和及時治療的認知不斷提高，推動了對抗生素、抗病毒藥物和輔助療法的需求。發展中地區醫療保健覆蓋範圍的擴大也進一步促進了市場成長。

關鍵成長要素包括疫苗接種率的提高、醫療保健支出的增加以及抗生素研發的進步。製藥公司正在投資開發對抗抗生素抗藥性的新治療方法。此外，以呼吸系統疾病管理為重點的公共衛生政策也有助於提高患者獲得治療的機會。診斷工具的改進也有助於提高治療性介入的有效性。

展望未來，對標靶治療和聯合治療的持續研究預計將對市場產生積極影響。疫苗接種計劃的擴大將影響治療模式。醫療基礎設施不斷完善的新興市場具有很高的成長潛力。由於呼吸系統健康仍然是全球關注的重點，預計對肺炎治療的需求將穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球肺炎治療市場：依產品分類

• 市場分析、洞察與預測
• 藥物
• 疫苗
• 氧氣療法

第5章：全球肺炎治療市場：依感染疾病

• 市場分析、洞察與預測
• 院內獲得性肺炎（HAP）
• 社區型肺炎（CAP）
• 人工呼吸器相關性肺炎（VAP）

第6章：全球肺炎治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外
• 其他

第7章：全球肺炎治療市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 居家照護
• 專科診所
• 其他

第8章 全球肺炎治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AstraZeneca
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Lupin

The Pneumonia Therapeutics Market size is expected to reach USD 7.52 Billion in 2034 from USD 3.28 Billion (2025) growing at a CAGR of 9.66% during 2026-2034.

The Global Pneumonia Therapeutics Market is experiencing steady growth due to the high prevalence of respiratory infections worldwide. Pneumonia remains a significant cause of morbidity and mortality, particularly among children and elderly populations. Increasing awareness about early diagnosis and timely treatment is driving demand for antibiotics, antivirals, and supportive therapies. Expanding healthcare access in developing regions further supports market growth.

Key growth drivers include rising vaccination coverage, increasing healthcare expenditure, and advancements in antimicrobial drug development. Pharmaceutical companies are investing in novel therapies to address drug-resistant strains. Additionally, public health initiatives focused on respiratory disease management are boosting treatment accessibility. Improved diagnostic tools also contribute to effective therapeutic interventions.

Looking ahead, the market is expected to benefit from continued research into targeted and combination therapies. Increasing adoption of preventive vaccination programs will influence treatment patterns. Emerging markets improving healthcare infrastructure present strong growth potential. As respiratory health remains a global priority, pneumonia therapeutics demand is projected to grow steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Drugs
• Vaccine
• Oxygen Therapy

By Infection

• Hospital-Acquired Pneumonia (HAP)
• Community-Acquired Pneumonia (CAP)
• Ventilator-Associated Pneumonia (VAP)

By Route of Administration

• Oral
• Parenteral
• Others

By End Use

• Hospitals
• Homecare
• Specialty Clinics
• Others

COMPANIES PROFILED

• AstraZeneca, Eli Lilly and Company, F HoffmannLa Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Oxygen Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY INFECTION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Infection
• 5.2. Hospital-Acquired Pneumonia (HAP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Community-Acquired Pneumonia (CAP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Ventilator-Associated Pneumonia (VAP) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Infection
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Infection
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Infection
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Infection
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Infection
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PNEUMONIA THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca
  • 10.2.2 Eli Lilly And Company
  • 10.2.3 F. Hoffmann-La Roche Ltd
  • 10.2.4 Mylan N.V
  • 10.2.5 Teva Pharmaceutical Industries Ltd
  • 10.2.6 Sanofi
  • 10.2.7 Novartis AG
  • 10.2.8 Sun Pharmaceutical Industries Ltd
  • 10.2.9 Aurobindo Pharma
  • 10.2.10 Lupin